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Abstract
Lactoferrin is an iron-binding glycoprotein implicated in particular in the control of immune functions and cell
proliferation. We have investigated its involvement, at inflammatory concentrations, in cancer progression. We report that
 .lactoferrin has a significant effect on natural killer NK cell cytotoxicity against haematopoietic and breast epithelial cell
 .  .lines. Lactoferrin increases cytolysis at a low concentration 10 mgrml while at a high concentration 100 mgrml it
modulates cytolysis depending on the target cell phenotype. By pre-treatment of either NK cells or target cells with
lactoferrin, we have demonstrated that the lactoferrin effect is due both to a modulation of NK cell cytotoxicity and the
target cell sensitivity to lysis. Lactoferrin binds to 91% of the naturally heterogeneous CD56dimrbright NK cell population
and increases the NK cell cytotoxic activity at low concentrations. High concentrations of lactoferrin seem to be toxic for
the CD56bright NK cells and decrease NK cell cytotoxicity. Lactoferrin also exerts an effect on target cells depending on the
cell phenotype. It does not modify the susceptibility to lysis of haematopoietic cells such as Jurkat and K-562 cells, but does
significantly increase that of the breast and colon epithelial cells. We have also demonstrated that lactoferrin inhibits
epithelial cell proliferation by blocking the cell cycle progression. q 1998 Elsevier Science B.V.
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1. Introduction
w xLactoferrin, also called lactotransferrin 1 , is an
iron binding glycoprotein synthesized by epithelial
cells and precursors of polymorphonuclear cells.
Abbreviations: mAbs, monoclonal antibodies; PE, phyco-
erythrin; BSA, bovine serum albumin; Lf, lactoferrin; HyF-Lf,
w  . x 4 .5- 2- carbohydrazino methyl -thio acetyl amino-fluorescein la-
belled lactoferrin; NK cells, natural killer cells
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Lactoferrin is mainly found in external secretions
such as breast milk and in neutrophil secondary
w xgranules 2 . More recently, some observations possi-
bly suggest an important role for lactoferrin in the
w xprimary defense against tumorigenesis 3 . It has been
shown that lactoferrin regulates the development of
w xtumour by a direct effect on tumour cells 4 . How-
ever, the activity of lactoferrin on cell proliferation
remains highly controversial. In fact, it has been
reported that lactoferrin promotes the proliferation of
w xcell lines 5 and has no effect on lymphocyte prolif-
w x w xeration 6 or inhibits mammary cell growth 7 .
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These opposite effects on tumour cells may be corre-
lated to the phenotype and the lactoferrin receptor
expression. In fact, lactoferrin binds to both high
w xaffinity specific receptors 8,9 and to low affinity
w xbinding sites such as glycosaminoglycans 10–12 .
In previous works, the binding parameters of hu-
man lactoferrin to haematopoietic and epithelial cell
lines of various origins were investigated. Lactoferrin
binds to haematopoietic cells such as the lympho-
blastic T cells Jurkat and the K-562 erythroleukemia
cells. The Jurkat cell line possesses a membrane
bound receptor which interacts with lactoferrin with a
dissociation constant of 80 nM and 0.3=106 sites
w x w x13 . Garre et al. 14 found that K-562 cells exhibit´
10=106 binding sites for lactoferrin with a high
 .affinity 25 nM . Lactoferrin enters these cells via
receptor mediated endocytosis where it is almost
w xdegraded in the lysosomal compartment 14,15 . Hu-
man lactoferrin also binds to various epithelial cells,
in particular to breast non-malignant SV-40 immor-
 .talized cells HBL-100 , to breast carcinoma cells
 . w xMCF-7 16 and to various subclones of the colon
w xadenocarcinoma cell line HT-29 17,18 . The dissoci-
ation constant is about 200 nM with more than
1=106 sites for these breast cells. HT29-18-C1 cells
exhibit 5.8=106 binding sites with relatively low
 .affinity 840 nM . In the colon cells, a large part of
surface bound lactoferrin is not internalized under
w xphysiological conditions 17,18 . In contrast to
haematopoietic cells, lactoferrin binds to these epithe-
lial cells and remains for the most part at the cell
w xsurface 16,18,19 . Lactoferrin is not internalized in
these various cells, suggesting that the intracellular
effects of lactoferrin in these breast and colon epithe-
lial cells differ from those in haematopoietic cell
lines.
Recently, it was shown that the antitumoral activ-
ity of lactoferrin may be explained by the modulation
 .of the natural killer NK cell and lymphokine-
w xactivated killer cell cytotoxicity 3,20 . The mecha-
nisms by which lactoferrin modulates the cytolysis of
tumour cells by NK cells is poorly understood. We
have hypothesized that lactoferrin could modulate the
biological responses of either NK cells or target cells
by interactions with lactoferrin receptors found on
these two cell types.
As the parameters for the lactoferrin binding to
Jurkat cells and epithelial cell lines are different, we
compared the cytolysis of these two kinds of cells by
NK cells, in the presence or absence of lactoferrin. In
a second step, to understand the events induced by
the presence of lactoferrin, we analysed the effects of
lactoferrin on cytolysis when it is incubated with NK
cells or target cells, respectively. Finally, to define
the mechanism of lactoferrin activity on cancerous
epithelial cells, we determined its effects on prolifera-
tion and induction of cell death.
The NK cell population is naturally heterogeneous;
it contains a majority of CD56dim cells and a minority
bright w xof CD56 21 . We demonstrated that on the
heterogeneous NK cell population, 91% of the cells
bind lactoferrin. Low concentrations of lactoferrin
lead to the activation of NK cell cytotoxicity. High
concentrations of lactoferrin seem to be toxic for the
CD56bright NK cells. Lactoferrin also acts on target
cell sensitization to lysis according to the phenotype
and the nature of the lactoferrin receptor. We demon-
strated that lactoferrin inhibits breast and colon ep-
ithelial cell proliferation by blocking the cell cycle
progression at the G1 to S transition or at the begin-
ning of the S phase. This result points to the potential
role of lactoferrin in providing protection from tu-
mour development.
2. Materials and methods
2.1. Cells
The effector cells were prepared from the citrated
blood of healthy donors by lymphoprep gradient sep-
w xaration 22 . Monocytic cells were extensively de-
pleted by adherence to plastic. Preparations of CD56q
 .NK cells purity: 85.5"5.5% were isolated by neg-
 .ative selection using monoclonal antibodies mAbs
 .against CD3 Immunotech, Marseille, France . The
effect of lactoferrin on NK cells was measured simul-
taneously on this preparation and on cells that had
undergone a second negative selection purity of NK
. cells: 95"3.2% using anti-CD20 mAbs Immuno-
.tech to eliminate an increase of NK cell cytotoxicity
after activation of B cells by lactoferrin. Briefly,
anti-CD3 or anti-CD20 mAbs were fixed on a tissue
 .culture dish in Tris 0.05 M –HCl buffer pH 9.5 for 4
h at 208C. The cellular suspension was added to the
fixed mAbs for 1 h at 378C. Effector cells were
finally resuspended in the RPMI medium.
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Cancerous haematopoietic cells and various epithe-
lial cells were used as target cells. Jurkat cells
 .lymphoblastic T-cell line ECACC and the erythro-
 .leukemia cell line K-562 ATCC were grown in
 .RPMI 1640 medium Gibco-BRL, Eragny, France
supplemented with 2 mM L-glutamine Eurobio, Les
.  .Ulis, France , 50 mgrml of gentamycin Gibco-BRL
 .and 10% of fetal calf serum FCS . Human breast
 .cancer epithelial cells MCF-7 ATCC , and HBL-100
SV40 immortalized human breast epithelial cell line,
.reportedly non-tumorigenic in nude mice , were
grown in Eagle’s minimal essential medium Gibco-
.BRL containing 10% FCS, 1% non-essential amino
 .acids Eurobio , 2 mM L-glutamine, 5 mgrml insulin
 .Endopancrine, Organon, Serifontaine, France , peni-
cillin and gentamycin at 378C, 5% CO . HT29-18-C1,2
a subclone of the human colon adenocarcinoma cell
line HT-29, was cultured in Dulbecco’s modified
 .Eagle’s medium Gibco-BRL supplemented with
10% FCS, 2 mM L-glutamine and 50 mgrl gen-
 .tamycin Gibco-BRL at 378C, 10% CO .2
2.2. Preparation of lactoferrin
Lactoferrin was prepared from a single human
lactoserum by ion-exchange chromatography as pre-
w x  .viously described 23 . The degree of purity )99%
of human lactoferrin was checked by 10% SDS-poly-
 .acrylamide gel electrophoresis PAGE and High
 .Pressure Liquid Chromatography HPLC .
Lipopolysaccharides were removed by chromatogra-
phy through a detoxi-gel column Pierce Chemicals,
.Rockford, IL, USA . The effects observed with our
purified lactoferrin were verified with lactoferrin pur-
 . chased from Calbiochem purity )99% La Jolla,
.CA, USA .
 .Fluorescent lactoferrin HyF-Lf was obtained by
w  . xcomplexing the 5- 2- carbohydrazino methyl -
4 .thio acetyl amino-fluorescein to lactoferrin according
w xto the technique described by Leveugle et al. 9 .
2.3. Cytotoxicity assay
Target cells were incubated with 20 mCi
51 51  .CrNa CrO ICN Biomedical, Irvine, CA, USA2 4
at a cell density of 2=105 in 100 ml RPMI. The
adherent epithelial cells, at a cell density of 5=
103rwell in 100 ml of medium, were labelled by
addition of 1 mCi 51Crrwell. Effector cells were
added at effectorrtarget ratios ranging from 5:1 to
80:1. At the end of the 12-h 51Cr assay, cells were
collected by centrifugation; an aliquot of supernatant
was collected from each well and the 51Cr released
was counted using a gamma counter 1282 Com-
.pugamma, LKB Wallac, Turky, Finland . The per-
centage of chromium released was calculated accord-
ing to the following equation: experimental cpmy
.  .control cpm r maximal cpmycontrol cpm =100.
Maximum 51Cr release was obtained by incubating
 3 .target labelled cells 5=10 cells into medium con-
taining 1% Triton X-100. Spontaneous release con-
. 3trol cpm was determined by incubation of 5=10
target labelled cells into medium. The ratio T rTmin max
did not exceed 3.7% for all the cytotoxic assays
performed.
Global effect of lactoferrin on cytotoxicity was
determined by adding lactoferrin at the beginning of
the cytotoxicity assay at concentrations of 10 mgrml
or 100 mgrml. Lactoferrin was maintained through-
out the chromium release assay. The effects of lacto-
ferrin on either NK cell activity or target cell sensitiv-
ity to lysis were also investigated. In order to deter-
mine the lactoferrin effect on NK cell cytotoxicity,
cells were pre-treated with lactoferrin concentration
.ranging from 0 to 100 mgrml for 12 h at 378C in
RPMI medium. Cells were washed just before the
cytotoxicity assay to eliminate lactoferrin excess.
Similar protocol was used to evaluate the effect of
lactoferrin on target cell sensitivity to lysis.
2.4. Lactoferrin binding to NK cells
We first verified the lactoferrin binding to NK
cells by cytofluorimetry. NK cells were washed twice
with PBS and 5=105 cells were stained with 10 ml
 .of mAbs against CD56 Sigma for 1 h at 48C. Then,
5 ml of antibodies against mouse IgG coupled to
 .phycoerythrin PE , 10 ml of HyF-lactoferrin at con-
centrations ranging from 1 to 20 mgrml and 50
molar excess of unlabelled lactoferrin were added for
1 h at 48C. The non-specific control was performed
by incubating the cells with Abs against mouse IgG,
HyF-lactoferrin and unlabelled lactoferrin in the ab-
sence of a staining with mAbs against CD56. Stained
cells were washed and analysed on a Becton-Dickin-
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son FACScan flow cytofluorimeter Becton Dickin-
.son Immunocytometry Systems, San Jose, CA, USA .
2.5. Effect of lactoferrin on target cells
Cell proliferation was evaluated by thymidine up-
take. Epithelial cell lines MCF-7, HBL-100 and
HT29-18-C1 were cultured in a 12 well plate at a cell
density of 40,000 cells per 500 ml of medium per
well. Then, cultures were incubated in the presence
of lactoferrin at concentrations ranging from 0 to 100
 3 .mgrml. After 24 h, 2 mCi of methyl- H thymidine
 .specific activity 50 Cirmmol, ICN, Biomedical
were added to each well for 4 h at 378C. The cells
were washed with PBS, and treated with cold 5%
trichloracetic acid for 45 min at 48C. Cells were
rinsed with water and solubilised with 0.3 M NaOH
for 1 h at 378C. The radioactivity of the cells was
measured using a beta counter Beckman, Fullerton,
.CA, USA .
The effect of lactoferrin on cell cycle progression
was determined by cytofluorimetry analysis. Epithe-
lial cell lines HBL-100, MCF-7 and HT29-18-C1
were grown to 50% confluence, and placed in a
serum-free medium for 24 h for the starvation-syn-
chronized experiments. The cells were cultured in a
medium of 1% FCS in the presence of 100 mgrml
lactoferrin for 48 h. They were then trypsinized and
fixed in cold 70% ethanol for 4 h. The fixed cells
were washed with PBS and incubated with 5 mg of
 .RNAse A Sigma per milliliter and stained with 25
mgrml of propidium iodine for 1 h at 378C. The
stained cells were analysed on a FACscan cytofluo-
rimeter using the cellFIT Software program.
3. Results
3.1. Effect on cytolysis of lactoferrin added simulta-
neously to NK cells and target cells
To test NK cell cytotoxicity in the presence of
lactoferrin, lactoferrin was added to the medium and
maintained throughout the chromium release assay.
Divergent results were obtained depending on cellu-
lar type and lactoferrin concentration. Whatever the
effectorrtarget ratio chosen, the addition of lactofer-
 .rin 10 mgrml resulted in a slight but significant
increase of up to 15% in the lytic ability of the NK
cells with regard to the haematopoietic Jurkat and
 .K-562 cell lines Fig. 1A . In contrast, a high concen-
 .tration of lactoferrin 100 mgrml decreased by about
Fig. 1. Effect of lactoferrin on haematopoietic cell cytolysis by NK cells. Lactoferrin is added simultaneously to the effector and target
 .  .cells at the beginning of NK cytotoxic assay. At a low concentration 10 mgrml , lactoferrin I enhances spontaneous cytotoxicity on
 .  .  .the haematopoietic cell lines A , while at high concentration 100 mgrml , it decreases cytolysis of the haematopoietic cells B as
 .compared to the control B . Cytolysis is measured at the three arbitrarily chosen effectorrtarget ratios of 20, 40, and 80, respectively.
Results are expressed as the mean"SEM of three experiments using three different donors.
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Fig. 2. Effect of lactoferrin on breast epithelial cell cytolysis by NK cells. Lactoferrin is added to the effector and the target cells at the
 .  .  .  .  .beginning of NK cytotoxic assay. At a low concentration 10 mgrml A or high concentration 100 mgrml B , lactoferrin I
 .increases the cytolysis of both human breast and colon epithelial cells as compared to the control B . Cytolysis is measured at the three
arbitrarily chosen effectorrtarget ratios, of 20, 40, and 80, respectively. The mean"SEM of experiments with three different donors are
shown.
16 to 20% the lysis of these haematopoietic cells
 .Fig. 1B .
Lactoferrin used at a low concentration 10
.mgrml increased NK cell cytotoxicity against the
HBL-100, MCF-7 and HT29-18-C1 epithelial cells
 .by about 25 to 35% Fig. 2A . A high concentration
 .of lactoferrin 100 mgrml increased cytotoxicity by
40 to 55% on the MCF-7 cancer cell line and by 60
to 65% on the HBL-100 and HT29-18-C1 cell lines
 .Fig. 2B .
The increase of cytolysis in the presence of lacto-
ferrin at a low concentration, whatever the target cells
used in this study, may be correlated to an activation
of the NK cells by lactoferrin. However, the diver-
 .Fig. 3. FACScan detection of lactoferrin binding to NK cells. The negative control A is determined by incubating cells with a 100-fold
 .molar excess of unlabelled lactoferrin and without CD56 mAbs. NK cells CD56 are analysed for expression of lactoferrin receptor as
 .described in Section 2 B . Quadrants were arranged such that non-specifically lactoferrin stained cells remained in the left quadrant.
Fluorescence 1sHyF-Lf signal; Fluorescence 2santi-CD56 PE signal. Data are representative of separate experiments with similar
results.
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gent results observed on haematopoietic and epithe-
lial cells at a high concentration of lactoferrin suggest
that lactoferrin acts not only on the effector cells but
also on the target cells, depending on the cell pheno-
type and the cell lactoferrin receptor expression. To
verify this hypothesis, we pre-treated the effector
cells and the target cells separately with lactoferrin.
3.2. Binding of lactoferrin to NK cells
In a first step, we checked the ability of NK cells
to bind lactoferrin using a double fluorescence stain-
ing in a cytofluorimetric analysis. The staining with
anti-CD56 mAbs and HyF-lactoferrin revealed that
91% of the CD56q cell population bound lactoferrin
 .Fig. 3A, B . The NK cell population was heteroge-
neous with a majority of CD56dim cells and a minor-
ity of CD56bright NK cells which bound more lacto-
ferrin. The binding was reversible in the presence of
unlabelled lactoferrin and was saturable at a concen-
tration of 10 mgrml, indicating that the binding of
lactoferrin was specific with an affinity of about 10y8
M.
3.3. Effect of lactoferrin on NK cell cytotoxicity
To confirm the modulation of NK cell cytotoxicity
in the presence of lactoferrin, the NK cells were
pre-treated with lactoferrin and the cytotoxicity of
NK cells with regard to the various target cells was
analysed. No significant effect of lactoferrin on NK
cells was observed with the haematopoietic cells
which showed a high sensitivity to lysis data not
.shown . In contrast, the HBL-100 and HT29-18-C1
cells showed less cytolysis than the haematopoietic
cells and permitted greater observation of NK cell
cytotoxicity activation by lactoferrin. Lactoferrin
modulated the cytotoxic activities of NK cells as a
function of its concentration. At low concentrations
 .of lactoferrin 10–25 mgrml , we observed a 25 to
40% increase in NK cytotoxicity. This result con-
firms the stimulation previously obtained in the pres-
ence of lactoferrin at 10 mgrml added simultane-
ously to NK and target cells. Higher concentrations
 .of lactoferrin 50–100 mgrml induced a significant
 .decrease in NK cell activity Fig. 4 , as confirmed by
the global effect of lactoferrin at 100 mgrml on
haematopoietic cell cytolysis.
Fig. 4. Effect of lactoferrin on NK cells. 51Cr release assay is
performed by using HBL-100 target cells. NK cells are pre-in-
cubated with lactoferrin concentration ranging from 0 to 100
.mgrml for 12 h, in RPMI medium supplemented with 10%
FCS. The bars indicate the mean"SEM of experiments per-
formed with three donors. p-0.01, Student’s t-test.
3.4. Effect of lactoferrin on target cell sensiti˝ity to
lysis
After pre-treatment of the target cell with lactofer-
rin, an effect of the lactoferrin on target cell sensitiv-
ity to lysis was observed according to cell phenotype
and lactoferrin concentration. Lactoferrin did not in-
duce significant variation in the haematopoietic Ju-
 .  .rkat Fig. 5A and K-562 Fig. 5B cell sensitivity to
NK cells. In contrast, the epithelial cell lines MCF-7,
 .  .HBL-100 Fig. 5C and HT29-18-C1 Fig. 5D were
more sensitive to lysis in the presence of lactoferrin.
The increase in sensitivity of these two types of
epithelial cells to NK cell lysis was similar and dose
dependent. These results were in agreement with our
previous experiment in Fig. 2A, which showed that
cytolysis of transformed or tumour epithelial cells
was greatly increased when lactoferrin at 100 mgrml
was added to the mixture containing the effector and
target cells. Furthermore, these results suggested that
the effects of lactoferrin were variable depending on
the cellular type.
Our results suggested that the modulation of cytol-
ysis by lactoferrin was mainly due to a sensitization
of certain target cells to NK cell lysis. In fact,
lactoferrin added to the medium during the chromium
release assay increased cytolysis of epithelial tumour
cells at 100 mgrml although lactoferrin slightly in-
hibited NK cell activity at this concentration. Thus,
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Fig. 5. Effect of lactoferrin on target cell sensitivity to lysis. Target cells are pre-incubated with lactoferrin concentration ranging from 0
.to 100 mgrml for 12 h in medium supplemented with 10% FCS. Target cell sensitization to lysis by lactoferrin was investigated on
 .  .  .  .Jurkat A , K-562 B , HBL-100 C and HT29-18-C1 D cells. Error bars indicate"SEM. p-0.05, Student’s t-test.
3  .  .Fig. 6. Effect of lactoferrin on H-thymidine incorporation in HBL-100 A and HT29-18-C1 B cell lines. Sub-confluent cells are
 .cultured with lactoferrin concentration ranging from 0 to 100 mgrml in 12-well plates for 24 h. After incubation with methyl
3H-thymidine for 4 h, the cells are lysed and incorporated methyl 3H-thymidine is counted. Each point is the mean"SEM of three
experiments.
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 .  .  .  .Fig. 7. FACScan analysis of untreated HBL-100 A and HT29-18-C1 B cells or lactoferrin 100 mgrml -treated HBL-100 C and
 .HT29-18-C1 D cultures. Cells are treated for 48 h prior to fixation and FACS analysis, as described in Section 2. Numbers indicate the
percentage of cells in the different phases of the cell cycle.
we tried to explain the mechanism of the biological
activity of lactoferrin on the epithelial cells.
3.5. Effect of lactoferrin on breast epithelial cell
proliferation and cell cycle
Lactoferrin at concentrations ranging from 0 to
. 3100 mgrml reduced H-thymidine incorporation in
a dose dependent manner in HBL-100, MCF-7 and
HT29-18-C1 cell lines. In particular, for the HBL-100
and HT29-18-C1 cell lines, 3H-thymidine incorpora-
tion was respectively decreased by about 47% Fig.
.  .6A and 56% Fig. 6B at a lactoferrin concentration
of 100 mgrml as compared to the control medium
.alone .
To understand the mechanism by which lactoferrin
inhibited epithelial cell proliferation, we investigated
the activity of lactoferrin on the cell cycle. Exponen-
tially growing HBL-100 cell culture exposed to 100
mgrml lactoferrin rapidly showed growth inhibition
as indicated by the lack of cell number increase after
48 h. Trypan Blue dye exclusion did not indicate
toxicity with this dose of lactoferrin )90% viability
.after 48 h . FACS analysis revealed that compared to
 .untreated cells Fig. 7A , a 48-h treatment with lacto-
ferrin resulted in a higher proportion of cells in S
 .phase Fig. 7B consistent with a block in the S phase
progression. Indeed, as described in the proliferation
test, lactoferrin inhibits the DNA synthesis. The cell
cycle of the MCF-7 and HT29-18-C1 cells was also
modified by lactoferrin. In fact, in the absence of
lactoferrin, MCF-7 and HT29-18-C1 cells proceeded
 .to enter the G2rM phase Fig. 7C . In contrast,
lactoferrin-treated cells remained arrested in the G1
 .phase Fig. 7D . These results confirm the potential
antiproliferative mechanism of lactoferrin on these
cells.
4. Discussion
The present findings represent the first demonstra-
tion that lactoferrin modulates cytolysis as a function
of the lactoferrin concentration and the target cell
phenotype, suggesting that lactoferrin acts on both
NK cells and target cells.
w xIn agreement with Nagler et al. 21 , we have
shown that NK cell population is heterogeneous with
a majority of CD56dim cells and a minority of
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CD56bright. We have demonstrated for the first time,
that both the CD56dim and CD56bright sub-populations
bind lactoferrin with however the CD56bright NK cells
binding more lactoferrin than the CD56dim cells. The
binding of lactoferrin on these cells suggests that
lactoferrin may act directly and specifically on the
NK cells. Indeed, we have demonstrated that pre-
treatment of NK cells for 12 h with low concentra-
 .tions of lactoferrin 10–25 mgrml enhanced NK
activity. Our results differ from those of Shau et al.
w x20 who found an increase in cytotoxicity only when
lactoferrin was added simultaneously to NK cells and
tumour cells at concentrations ranging from 7.5 to
750 mgrml. They did not observe any modification
of the cytotoxic activity when the NK cells were
pre-treated with lactoferrin. The differences in the
results may be due to the fact that firstly, the authors
did not use purified NK cells, but a total lymphocytic
population which may affect the lactoferrin effect on
the NK cell population, and secondly to the fact that
the pre-treatment of the NK cells was carried out
only for 30 min with very a high concentration of
 .lactoferrin 500 mgrml . This short-term treatment
of the NK cells with lactoferrin did not allow the
observation of the NK cell cytotoxicity modulation
by lactoferrin. Indeed, in the particular case of inter-
leukin-2, it was necessary to activate NK cells more
than 3 to 6 h in order to enhance cytotoxic activity
w x24 . Furthermore, we have demonstrated that the
increase in NK cell cytotoxicity induced by lactofer-
rin is only observed at low concentrations of lactofer-
rin; at high concentrations, lactoferrin decreased NK
cell activity. The physiologic level of lactoferrin in
plasma does not exceed 2 mgrml in healthy subjects
w x25 . Therefore, the slight increase in lactoferrin con-
w xcentration caused by degranulation of neutrophils 2
during inflammation induced by tumour development
could enhance NK cell functions in vivo. In contrast,
the high concentrations of lactoferrin 50–100
.mgrml used in vitro, can exert a toxic effect on NK
cells and decrease their cytotoxic activity. In fact, all
NK cells have the ability to mediate spontaneous
cytotoxicity. The CD56bright cells, which exert the
highest cytotoxic activity in the total CD56 NK cell
population, bind more lactoferrin than the CD56dim
cells. These CD56bright NK cells are sensitive to high
concentrations of lactoferrin. Thus, at a high concen-
tration of lactoferrin, only the CD56dim cells main-
tained spontaneous cytotoxic activity, explaining the
decrease in but not the disappearance of the cytotoxi-
city.
The antineoplastic activity of lactoferrin seems
also to be due to the direct action on target cells. We
have demonstrated a variability in the target cell
response to pre-treatment by lactoferrin. The differ-
ence in sensitivity of the haematopoietic and the
epithelial cells can be correlated to the target cell
phenotype. Indeed, lactoferrin presents a variety of
activities in vitro including control of proliferation
and differentiation. Lactoferrin mRNA, mainly de-
tected in normal breast epithelial tissues and in be-
nign proliferative lesions, is down-regulated in some
forms of cancer, such as human breast and colon
w xepithelial cancers 26,27 , suggesting that lactoferrin
is implicated in the tumour epithelial cell progression.
w xIn fact, Hurley et al. 7 reported that lactoferrin
inhibits mammary cell growth. Furthermore, this ef-
fect was also observed on the HT-29 cells. Indeed,
when transferrin was replaced by lactoferrin, HT-29
w xcells were unable to proliferate for a long time 28 .
In our work, we have confirmed these previous ob-
servations and demonstrated that lactoferrin rapidly
inhibits the proliferation of the transformed and tu-
mour epithelial cell lines by a block in the cell cycle
progression at the G1 to S transition. The extensive
and rapid modification of the cell cycle can explain
the increase in the sensitivity to lysis of the trans-
formed and tumour epithelial cells. In contrast, lacto-
ferrin induces a long term differentiation of the Jurkat
 .cell line unpublished data . Furthermore, lactoferrin
does not rapidly influence the K-562 cell prolifera-
tion, although there is a close relationship between
lactoferrin binding to these cells and their prolifera-
w xtive status 29 . The absence of rapid cell cycle
modifications in these haematopoietic cells does not
modify their sensitivity to NK cell lysis.
An alternative hypothesis is that the variability in
the target cell response to lactoferrin could depend on
the difference in the lactoferrin remaining at the cell
surface. Indeed, lactoferrin remaining at the target
cell surface could increase the contact with the NK
cells through its glycan moiety and lectins expressed
on the NK cell surface. Such an interaction has been
described for the rat c-lectin NKRP-1 and oligo-
w xsaccharides of proteoglycans 30 . In the case of the
Jurkat cells, lactoferrin binding to these cells occurs
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mainly through a high affinity receptor which allows
w xinternalization of lactoferrin 13,15 . Therefore, the
low concentration of lactoferrin at the target cell
surface can not enhance contact with NK cells and
does not increase the cytolysis of the Jurkat cells. In
contrast, the epithelial cells showed a dose-dependent
increase in their sensitivity to lysis. Lactoferrin bound
at the cell surface is not internalized and remains at
w xthe cell surface 16,18,19 where it can enhance the
cytolysis of these cells by NK cells.
In conclusion, the cell phenotype, the binding of
lactoferrin and the internalization process can explain
the variability in sensitivity of the cells studied. It
appears that the binding of lactoferrin to the cells is
mediated by various types of molecules which are
able to induce variable effects. However, the interac-
tion with the various lactoferrin receptors found on
these cells is not yet known and remains to be
determined.
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